Reliance Life Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RELIANCE LIFE
RELIANCE LIFE has five approved drugs.
Summary for Reliance Life
| US Patents: | 0 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Reliance Life
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reliance Life | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 211899-002 | May 25, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Reliance Life | CAPECITABINE | capecitabine | TABLET;ORAL | 211724-001 | Apr 27, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Reliance Life | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 217453-001 | May 20, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Reliance Life Sci | DECITABINE | decitabine | INJECTABLE;INTRAVENOUS | 217814-001 | Dec 19, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Reliance Life | CAPECITABINE | capecitabine | TABLET;ORAL | 211724-002 | Apr 27, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
